Search Results
Your search for ,now matches 6673 pages
Showing 4701 - 4750Mylin A. Torres, MD, Named Director of Winship’s Glenn Family Breast Center
Winship Cancer Institute of Emory University has named Mylin A. Torres, MD, the new Director of the Glenn Family Breast Center, effective January 19, 2016. She succeeds Ruth O’Regan, MD, who now heads the University of Wisconsin Division of Hematology and Oncology. Dr. Torres is Associate Professor ...
Radiolabeled Somatostatin Analog May Represent A Paradigm Change in the Treatment of Neuroendocrine Tumors
A radiolabeled somatostatin analog compound, 177Lu-DOTA0-Tyr3-Octreotate (Lu-177 dotatate), reduced the risk of disease progression or death by 79% in the international phase III NETTER-1 population of previously treated, advanced neuroendocrine tumors of midgut origin.1 Lu-177 dotatate belongs to...
Expert Point of View: Irvin M. Modlin, MD, and Eric Liu, MD
Two neuroendocrine tumor experts had slightly different reactions to the latest RADIANT-4 data. Irvin M. Modlin, MD, Emeritus Professor of Gastroenterological Surgery at Yale University School of Medicine, New Haven, Connecticut, said in an interview that he essentially restricts his use of...
Everolimus Effective in Neuroendocrine Tumors of Gastrointestinal Origin
In a subgroup analysis of the phase III RADIANT-4 trial, focusing on neuroendocrine tumors of gastrointestinal origin, the mTOR inhibitor everolimus (Afinitor) essentially doubled the median progression-free survival time, compared with placebo, researchers reported at the 2016 Gastrointestinal...
Study Links Normal Stem Cells to Aggressive Prostate Cancer
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer. The study proved that the prostate basal cell layer contains adult stem cells, which possess a unique gene-expression profile resembling the ...
Study Finds 36% Increase in Number of Male Smokers in India Over 17 Years
The number of men smoking tobacco in India rose by more than one third to 108 million between 1998 and 2015, according to a new study published in the journal BMJ Global Health. The study also found that cigarettes were replacing the traditional bidi, a small, inexpensive Indian cigarette,...
Eye Movement Affected in Some Former Childhood Cancer Patients
A study from Lund University in Sweden has shown that commonly used chemotherapy toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system. The results were published by Einarsson et al in PLOS One. It was not the former patients' ...
Jaclyn Biegel, PhD, Joins Children’s Hospital of Los Angeles as Director of Center for Personalized Medicine
Children’s Hospital Los Angeles (CHLA) has named Jaclyn Biegel, PhD, a leading academic expert on pediatric brain tumors, rhabdoid tumors, and cancer cytogenetics, as the Director of the Center for Personalized Medicine at CHLA. Dr. Biegel, who formerly served as Director of the Cancer Cytogenetics ...
Global Cancer: The Current Reality and the Future Need for Action
The estimated number of cancer cases worldwide in 2008 was 12.7 million, with 7.6 million deaths. By 2030, it is estimated that there will be 22 million newly diagnosed cancer cases and 12 million deaths, shocking to contemplate in dollars and human suffering. Although this impending disaster has...
Suresh S. Ramalingam, MD, Named Deputy Director of Winship Cancer Institute
Suresh S. Ramalingam, MD, an internationally recognized lung cancer physician-investigator, has been named Deputy Director of Winship Cancer Institute of Emory University. He will also serve as Assistant Dean for Cancer Research in the Emory School of Medicine. In his role as Winship’s Deputy...
Expect Questions About Updated Dietary Guidelines
The 2015–2020 Dietary Guidelines for Americans1 have generated comments and controversy, with some organizations expressing concern that the guidelines did not recommend limiting the consumption of red and processed meat. These organizations include the American Institute for Cancer Research...
Failure of Updated Dietary Guidelines to Advise Limiting Red and Processed Meat Deemed a ‘Missed Opportunity’
“A missed opportunity” is how Susan Higginbotham, PhD, RD, Vice President for Research, American Institute for Cancer Research (AICR), described the “failure” of updated dietary guidelines to recommend limiting consumption of red and processed meat. Doing so would have “the potential to save...
ASCO Announces New Award Recognizing Extraordinary Contributions to Cancer Survivorship Care
ASCO has announced the creation of the Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care, intended to recognize and promote the work of pioneers and leaders in the growing field of survivorship. The first award will be presented at the 2017 Cancer Survivorship...
Candid Discussions on Living With and After Cancer at An Evening for Cancer Survivors and Caregivers
On January 14, 2016, the Cancer Survivorship Symposium opened with An Evening for Cancer Survivors and Caregivers, an event featuring networking, a panel discussion, and an open forum to share the challenges of living with or after a cancer diagnosis. The audience included Symposium attendees as...
Rolapitant Reduces Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately and Highly Emetogenic Chemotherapy
In three phase III studies reported in The Lancet Oncology, the addition of the neurokinin-1 (NK-1) receptor antagonist rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in the prevention of chemotherapy-induced nausea and ...
Evolving Tools for Clinical Decision-Making
Value in cancer care—and how to define it—is a hot topic. There is general agreement that it is some measure of benefit vs cost, but “should the focus be on providing value to patients at a population level or at an individual level?” asked Alan Balch, PhD, CEO of the Patient Advocate Foundation,...
David J. McConkey, PhD, Named Director of Johns Hopkins Greenberg Bladder Cancer Institute
David J. McConkey, PhD, has been appointed Director of the Johns Hopkins Greenberg Bladder Cancer Institute. The institute was established in 2014 with a $15 million gift from Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife, Stephanie Cooper Greenberg, and a $30...
Expert Point of View: Elizabeth Plimack, MD
The Egyptian study presented by Brian Baumann, MD, of the University of Pennsylvania, Philadelphia, was a “valiant effort” to determine whether sequential adjuvant chemotherapy added to adjuvant radiation would improve disease-free survival, said formal discussant of this trial Elizabeth Plimack,...
Expert Point of View: Oliver Sartor, MD
“This platform has no selection bias. Phlebotomy samples are drawn at key decision points. We begin to see that heterogeneity of circulating tumor cells predicted for shorter progression and survival times with selected androgen receptor–directed therapies. We need to study this prospectively,”...
Expert Point of View: Bertram Wiedenmann, MD, PhD and Markus Moehler, MD, PhD
Commenting on the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) antibodies in tumors with mismatch repair deficiency, Bertram Wiedenmann, MD, PhD, Professor of Internal Medicine and Gastroenterology, Universitätsmedizin Berlin, Germany, suggested, “The efficacy of pembrolizumab...
Cost in the Context of Value for Cancer Medicines
Bringing new cancer therapies through the discovery and development process entails considerable risk and many years of study. It also requires substantial investment and incentives from the public and private sectors to fuel future investment and discovery. A system that rewards advances in cancer ...
Inherited Genetic Variations That Lead to Severe Drug Toxicity in Pediatric Leukemia Discovered
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children’s Research Hospital scientists led the study, results of which set the stage to expand the use of a...
Norwegian Male Cancer Survivors Less Likely to Reproduce
A study of all Norwegian men born between 1965 and 1985 showed that male cancer survivors are less likely to have children than those without a cancer diagnosis. “These findings are important for male cancer survivors, seeing as we can identify groups at risk of having reproduction...
Gene Previously Observed Only in Brain Is Important Driver of Metastatic Breast Cancer
When breast cancer becomes metastatic, patient survival is drastically reduced, prompting the need to explore the genes that may cause tumor cells to metastasize. Now, scientists from The Wistar Institute have shown that a gene that was once thought only to be found in the brain is also expressed...
Study Examines Evolution of Cancer
A novel Yale University study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead to more effective targets for treatment, said the researchers. The...
Preclinical Device Hits Pancreatic Tumors With Drug Cocktail, Sparing the Body
A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a team of researchers at the University of North Carolina at Chapel Hill has found that an implantable device can deliver a ...
Possible Marker for Recurring HPV-Linked Oropharyngeal Cancers
A retrospective analysis of human papillomavirus (HPV) antibodies in patients treated for oropharyngeal cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, said scientists at The Johns Hopkins...
The Sohn Conference Foundation Unveils The Sohn Precision Medicine Program at Columbia University Medical Center
The Sohn Conference Foundation unveiled The Sohn Precision Medicine Program at Columbia University Medical Center (CUMC) on January 14, 2016. Funded by a $1.5 million grant provided by The Sohn Conference Foundation over approximately a 3-year period, the Program will provide high-risk pediatric...
A Brain Tumor Diagnosis Has Taken My Life in New Directions
The first sign that I could have a life-threatening illness was a bout of severe dizziness, which sent me first to a general practitioner for a physical examination and then to an ear specialist for more tests. At just 24 and in excellent health, the sudden onset of dizziness didn’t initially set...
Certainty
The following essay by William N. Harwin, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. My wife...
James K.V. Willson, MD, Named Chief Scientific Officer of CPRIT
James K.V. Willson, MD, Associate Dean of Oncology Programs and Professor and Director of the Harold C. Simmons Comprehensive Cancer Center at University of Texas (UT) Southwestern Medical Center, has been named Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas...
New AJCC Precision Medicine Guidelines Aimed at Improving Personalized Cancer Treatment Plans for Patients
A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. These guidelines were...
A Pioneering Oncologist’s Roadmap Forward
Bookmark Title: The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable—and How We Can Get There Authors: Vincent T. DeVita, Jr, MD, and Elizabeth DeVita-Raeburn Publisher: Farrar, Straus and Giroux Publication date:...
Defibrotide Under Review for Transplant-Related Complication
A potentially fatal complication of hematopoietic stem cell transplantation may be reversed with the use of a novel drug currently under priority review at the U.S. Food and Drug Administration (FDA). Hepatic veno-occlusive disease/sinusoidal obstruction syndrome is usually a serious complication...
How Cancer and Its Treatments Affect Cognitive Function
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Bone Loss Associated With Leukemia Therapy Occurs Sooner Than Previously Thought
Investigators at Children’s Hospital Los Angeles (CHLA) have found that significant bone loss occurs during the first month of chemotherapy for acute lymphoblastic leukemia (ALL), which is far earlier than previously assumed. Results of the study were published by Orgel et al in the...
World Cancer Day 2016: We Can. I Can.
Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old). It has been estimated that the cost implications on world economies caused by cancer and the other...
For Postmenopausal Women With Ductal Carcinoma in Situ: NSABP B-35 and IBIS-II DCIS Trials Offer a Choice of Endocrine Therapy
The past year has produced an embarrassment of riches regarding the value of aromatase inhibitors for women with ductal carcinoma in situ of the breast. The long-awaited NSABP B-35 study matured and was reported by Margolese and colleagues at the 2015 ASCO Annual Meeting this past summer, followed...
ASCO Names Advance of the Year, Highlights Major Top Research Trends
Research is the bedrock of progress against cancer, and discoveries in cancer biology are moving from bench to bedside faster than ever. No recent advance has been more transformative than the rise of immunotherapy, particularly over the past year, making this treatment strategy ASCO’s Advance of...
Researcher Spotlight: Conquering Cancer With Dr. Wagle
When it comes to cancer, one of the most frustrating moments for patients and doctors alike is discovering a promising treatment has suddenly stopped working. Generally, this occurs when cancer develops resistance and finds ways to bypass a treatment’s effects. Cancer drug resistance happens more...
ASCO Names Cancer Advance of the Year: Immunotherapy
At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...
Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?
Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....
Selected Abstracts From 2015 San Antonio Breast Cancer Symposium
The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...
Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma
Patients with multiple myeloma now have access to an all-oral regimen, with the recent approval of the oral proteasome inhibitor ixazomib (Ninlaro) in previously treated patients. New pairings for the drug in relapsed/refractory and newly diagnosed patients are being studied, with investigators...
'Doctor, We Prayed for You'
A 70-year-old female patient underwent a cardiac procedure to repair her mitral valve, and at the same time, she also underwent a coronary artery bypass grafting. She had an uneventful course for the first four postoperative days. On the sixth postoperative day, she started complaining of abdominal ...
Abnormal Fused Gene Is a Triple Threat in Driving Pediatric Brain Tumors
Oncology researchers have discovered that an abnormal fused gene that drives pediatric brain tumors poses a triple threat, operating simultaneously through three distinct biologic mechanisms—the first such example in cancer biology. The study was published by Bandopadhayay et al in Nature...
Higher Dietary Fiber Intake in Adolescence and Young Adulthood May Reduce Breast Cancer Risk
Women who eat more high-fiber foods during adolescence and young adulthood—especially fruits and vegetables—may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H. Chan...
USPSTF Recommendation Confirms Value of Screening Mammography
The recently updated U.S. Preventive Services Task Force (USPSTF) recommendation once again confirmed the value of screening mammography, concluding that the benefit of mammography outweighs the harms of screening in all age groups from age 40 through age 74. It emphasizes that both women and...
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
Famed Cancer Biostatistician, Norman Breslow, PhD, Dies
A longitudinal case-controlled analysis of the probability of attaining normality after achieving 60: A perspective from the social sciences based on expert ethnographic insights.” So begins a long and charmingly erudite birthday card to internationally regarded biostatistician Norman Breslow, PhD, ...
